Cargando…

Does dapagliflozin regress left ventricular hypertrophy in patients with type 2 diabetes? A prospective, double-blind, randomised, placebo-controlled study

BACKGROUND: Patients with diabetes have a two to fourfold increased risk for development of and death from cardiovascular disease [CVD]. The current oral hypoglycaemic agents result in limited reduction in this cardiovascular risk. Sodium glucose linked co-transporter type 2 [SGLT2] inhibitors are a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brown, Alexander J.M., Lang, Chim, McCrimmon, Rory, Struthers, Allan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569551/ https://www.ncbi.nlm.nih.gov/pubmed/28835229 http://dx.doi.org/10.1186/s12872-017-0663-6

Ejemplares similares

A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial
por: Brown, Alexander J M, et al.
Publicado: (2020)

Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial
por: Singh, Jagdeep S.S., et al.
Publicado: (2020)

Renal and Cardiovascular Effects of sodium–glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial
por: Mordi, Natalie A, et al.
Publicado: (2017)

Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial
por: Mordi, Natalie A., et al.
Publicado: (2020)

Allopurinol treatment adversely impacts left ventricular mass regression in patients with well-controlled hypertension
por: Gingles, Christopher R., et al.
Publicado: (2019)

Left Ventricular Hypertrophy in Diabetic Cardiomyopathy: A Target for Intervention
por: Mohan, Mohapradeep, et al.
Publicado: (2021)

Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial
por: Noman, Awsan, et al.
Publicado: (2010)

Cardiorenal Systems Modeling: Left Ventricular Hypertrophy and Differential Effects of Antihypertensive Therapies on Hypertrophy Regression
por: Hallow, K. Melissa, et al.
Publicado: (2021)

Genetic variants predicting left ventricular hypertrophy in a diabetic population: a Go-DARTS study including meta-analysis
por: Parry, Helen M, et al.
Publicado: (2013)

Telmisartan regresses left ventricular hypertrophy in caveolin-1 deficient mice
por: Kreiger, Marta H, et al.
Publicado: (2010)

Marked Regression of Left Ventricular Hypertrophy after Outflow Desobliteration in HOCM
por: Dimitriadis, Zisis, et al.
Publicado: (2012)

Regression of Left Ventricular Hypertrophy in Patients Combined with Peritoneal Dialysis and Hemodialysis
por: Luyan, Gao, et al.
Publicado: (2022)

Glucose Sensing During Hypoglycemia: Lessons From the Lab
por: McCrimmon, Rory
Publicado: (2009)

Left Ventricular Hypertrophy and Ventricular Tachyarrhythmia: The Role of Biomarkers
por: Bacharova, Ljuba, et al.
Publicado: (2023)

Detection of Left Ventricular Hypertrophy Using Bayesian Additive Regression Trees: The MESA
por: Sparapani, Rodney, et al.
Publicado: (2019)

Regression of the Left Ventricular Hypertrophy in Patients with Essential Hypertension on Standard Drug Therapy
por: Ahmed, Shah Newaz, et al.
Publicado: (2020)

A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial
por: Mohan, Mohapradeep, et al.
Publicado: (2019)

Consequences of recurrent hypoglycaemia on brain function in diabetes
por: McCrimmon, Rory J.
Publicado: (2021)

Remembrance of things past: The consequences of recurrent hypoglycaemia in diabetes
por: McCrimmon, Rory J.
Publicado: (2022)

Regression of Left Ventricular Hypertrophy in a Case of Sarcomeric Hypertrophic Cardiomyopathy: An Unexpected Outcome
por: Cabrera Borrego, Eva, et al.
Publicado: (2020)

Prognostic implication of left ventricular hypertrophy regression after antihypertensive therapy in patients with hypertension
por: Kim, Hyue Mee, et al.
Publicado: (2022)

Microvascular disease and heart failure with reduced and preserved ejection fraction in type 2 diabetes
por: Mordi, Ify R., et al.
Publicado: (2020)

Moexipril and left ventricular hypertrophy
por: Chrysant, George S, et al.
Publicado: (2007)

Left ventricular hypertrophy: is it really?
por: Mikolich, J Ronald, et al.
Publicado: (2013)

Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: A randomised, double-blind, placebo-controlled crossover trial
por: Laursen, Jens Christian, et al.
Publicado: (2021)

An Increased B-Type Natriuretic Peptide in the Absence of a Cardiac Abnormality Identifies Those Whose Left Ventricular Mass Will Increase Over Time
por: Nadir, M. Adnan, et al.
Publicado: (2015)

Hypoglycemia in Type 1 Diabetes
por: McCrimmon, Rory J., et al.
Publicado: (2010)

Organic Nitrates Favor Regression of Left Ventricular Hypertrophy in Hypertensive Patients on Chronic Peritoneal Dialysis
por: Li, Han, et al.
Publicado: (2013)

Left Ventricular Hypertrophy Regression During Antihypertensive Treatment in an Outpatient Clinic (the Campania Salute Network)
por: Lønnebakken, Mai Tone, et al.
Publicado: (2017)

Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial
por: Kosiborod, Mikhail N, et al.
Publicado: (2021)

Myocardial Energetics in Left Ventricular Hypertrophy
por: Jameel, Mohammad N, et al.
Publicado: (2009)

SGLT inhibitor adjunct therapy in type 1 diabetes
por: McCrimmon, Rory J., et al.
Publicado: (2018)

Clinical approaches to treat impaired awareness of hypoglycaemia
por: Farrell, Catriona M., et al.
Publicado: (2021)

Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design
por: Singh, Jagdeep S. S., et al.
Publicado: (2016)

Independent Influence of Overweight and Obesity on the Regression of Left Ventricular Hypertrophy in Hypertensive Patients: A Meta-analysis
por: Zhang, Kun, et al.
Publicado: (2014)

Progression and regression of left ventricular hypertrophy and myocardial fibrosis in a mouse model of hypertension and concomitant cardiomyopathy
por: Kwiecinski, Jacek, et al.
Publicado: (2020)

Regression of Electrocardiographic Left Ventricular Hypertrophy and Strain Pattern Using Pharmacotherapy in a Patient With Dilated Cardiomyopathy
por: Hashimoto, Toru, et al.
Publicado: (2020)

Prevalence of left ventricular hypertrophy in children and young people with primary hypertension: Meta-analysis and meta-regression
por: Sinha, Manish D., et al.
Publicado: (2022)

Impaired hypoglycaemia awareness in type 1 diabetes: lessons from the lab
por: McNeilly, Alison D., et al.
Publicado: (2018)

Electrocardiographic Criteria for Left Ventricular Hypertrophy in Children
por: Rijnbeek, Peter R., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_a4i7inj8ocvgtacf51a5m2h44a